Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum

Clinical Chemistry

Volumn 42, Issue 7, 1996, Pages 1034-1041

  Piironen, Timo ^a   Lövgren, Janita ^b   Karp, Matti ^a   Eerola, Riitta ^a   Lundwall, Åke ^b   Dowell, Barry ^c   Lövgren, Timo ^a   Lilja, Hans ^b   Pettersson, Kim ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c ABBOTT LABORATORIES   (United States)

Author keywords

complexes; monoclonal antibodies; prostate cancer; prostate specific antigen; protease inhibitors

Indexed keywords

KALLIKREIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FLUOROMETRY; GEL FILTRATION; HAMSTER; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROSTATE CARCINOMA; SEQUENCE HOMOLOGY;

ANIMALIA; CRICETINAE;

EID: 0029902282     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.7.1034     Document Type: Article

References (38)

1. Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 1994;99:C1-6.
2. Vihinen M. Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem Biophys Res Commun 1994;3:1251-6.
3. Schedlich U, Bennets B, Morris BJ. Primary structure of human glandular kallikrein gene. DNA 1987;6:429-37.
4. Lilja H, Abrahamsson PA, Lundwall Å. Semenogelin, the predominant protein in human semen. J Biol Chem 1989;37:1618-25.
5. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of human prostate specific antigen. Invest Urol 1979;17:159-63.
6. Yu H, Diamandis EP, Sutherland D. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-9.
7. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54-8.
8. Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995;41:204-10.
9. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80:281-5.
10. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth-factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53.
11. Chapdelaine P, Paradis G, Tremblay RR, Dubé JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.
12. Henttu P, Lukkarinen O, Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990;45: 654-60.
13. Young CY, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992;31:818-24.
14. Henttu P, Liao S, Vihko P. Androgens up-regulate the human prostate-specific messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992;130:766-72.
15. McCormack RT, Wang TJ, Rittenhouse HG, Wolfert RL, Finlay JA, Lilja H, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
16. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.
17. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
18. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
19. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
20. Brawer MK. Prostate specific antigen. Acta Oncol 1991;30: 161-8.
21. Nadji M, Tabei SJ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR. Prostate-specific antigen: an immunohistological marker for prostatic neoplasms. Cancer 1981;48:1229-32.
22. Papsidero LD, Wang MC. Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40:2428-32.
23. Duffy MJ. New cancer markers. Ann Clin Biochem 1989;26:379-87.
24. Brawer MK, Lange PH. Prostate specific antigen in management of prostatic carcinoma. Urology 1989;5(Suppl):11-6.
25. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
26. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-7.
27. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate specific antigen in serum as screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
28. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
29. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, et al. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-95.
30. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
31. 1-antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
32. 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 1995;41:1273-82.
33. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed, and total serum PSA: the establishment of reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
34. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
35. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG. Multiple forms of prostate-specific antigen in serum measured differently in equimolar- and skewed-response assays [Letter]. Clin Chem 1995;41:125-6.
36. Stephenson RA, Greskovich FJ, Fritsche HA, James BC. Ratio of polyclonal-monoclonal prostate specific antigen levels: discrimination of nodal status in prostate tumors that produce low marker levels. Urol Clin North Am 1991;18:467-71.
37. Bluestein B, Zhou A, Tewari P, Comerci C, Schubert W, Larsen F. Multi-site clinical evaluation of an automated chemiluminescent immunoassay for prostate specific antigen (ACS PSA). J Tumor Marker Oncol 1992;7:41-60.
38. Klee G, Griffin B, Young C, Tindall D, Finlay J, Saedi M. A competitive chemiluminescent assay for a PSA homologue: human glandular kallikrein (hK2) [Abstract]. Clin Chem 1995;S6: 220.